Noubar Afeyan

Noubar Afeyan (born 1962) is a U.S.-based healthcare billionaire in Massachusetts with an estimated net worth of ~$1.9B. SEC filings under “AFEYAN NOUBAR” show extensive insider-reporting activity tied to multiple biotech companies, including Moderna (MRNA), Editas Medicine (EDIT), Denali Therapeutics (DNLI), Syros Pharmaceuticals (SYRS), and Seres Therapeutics (MCRB) SEC EDGAR, RTB.

Business & SEC Activity

SEC EDGAR lists 318 total filings associated with Afeyan, including 291 insider filings, which are disclosures typically required when corporate insiders (like officers, directors, or large shareholders) report ownership and transactions in public-company stock SEC EDGAR. Recent filings include multiple Form 4 reports (used to disclose insider trades) and Form 3 reports (initial statements of beneficial ownership), plus a Form 144 (notice of a proposed sale of restricted or control securities) SEC EDGAR.

Philanthropy

Two foundations are listed in 2023 IRS Form 990 data: the Noubar & Anna Afeyan Foundation (DE) and Afeyan Foundation For Armenia Inc (MA) ProPublica 990. Combined, they reported total assets of $18,037,906 and total grants paid of $0 in tax year 2023, despite reporting revenues of $2,264,432 and $5,037,063 respectively ProPublica 990.

Political Activity

FEC records show 37 contributions totaling $76,320 from 1995-06-30 to 2025-09-30 FEC. The party breakdown shows $39,650 to Democratic recipients, $7,800 to Republican recipients, and $28,870 categorized as Unknown FEC. Top recipients by amount include ARMENIAN AMERICAN PAC (ARMENPAC) ($15,000), BILL CASSIDY FOR US SENATE ($6,800), JAKE AUCHINCLOSS FOR CONGRESS ($6,400), SODERBERG FOR CONGRESS ($5,400), and KOUTOUJIAN FOR CONGRESS ($5,200) FEC.

In the News

Recent coverage includes reporting on Flagship-backed Generate Biomedicines’ IPO and early trading performance (Reuters and Bloomberg, Feb. 2026) NewsAPI. Other headlines include a report on Alltrna undergoing a third layoff round and cutting 35% of jobs (Fierce Biotech, March 2026) and a Boston Globe story discussing Moderna and FDA/political dynamics (Feb. 2026) NewsAPI.